1515.Hk
1515.HK operates in the Health Care Providers & Services industry, generating revenue through healthcare-related activities, though specific operational details are unclassified in the available data.
Business. West Holdings Corp (1515.HK) is a healthcare company engaged in pharmaceutical activities within the Healthcare Facilities & Services industry. The firm operates on a service-revenue model and is headquartered in Hong Kong, where it is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic presence are not available.
Analyst recommendations
2 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
West Holdings Corp (1515.HK) is a healthcare company engaged in pharmaceutical activities within the Healthcare Facilities & Services industry. The firm operates on a service-revenue model and is headquartered in Hong Kong, where it is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic presence are not available.
The company maintains a conservative capital structure with a debt-to-equity ratio of 0.13, indicating low leverage relative to equity. Total assets stand at 12.9 billion CNY, supported by 6.5 billion CNY in total equity and 6.4 billion CNY in liabilities. Long-term debt is limited to 853 million CNY, while cash and equivalents amount to 940 million CNY. However, liquidity appears constrained, as evidenced by a current ratio of 0.64, which suggests potential short-term solvency pressure despite the low overall debt load.
Profitability metrics indicate modest returns, with a return on equity (ROE) of 7.57% and a return on assets (ROA) of 3.84%. The company generated 9.18 billion CNY in revenue, resulting in a gross profit of 1.44 billion CNY and an operating income of 719 million CNY. Net income reached 496 million CNY, yielding a net margin of approximately 5.4%. These returns are below typical industry medians for high-growth healthcare providers, reflecting the mature or low-margin nature of the current business model.
- The company trades at a low valuation multiple with a P/E of 6.61 and EV/EBITDA of 4.44, suggesting potential undervaluation or market skepticism.
- Liquidity is tight with a current ratio of 0.64, despite low long-term debt and a healthy cash position of 940 million CNY.
- Profitability is modest with an ROE of 7.57% and ROA of 3.84%, indicating efficient but not exceptional capital utilization.
- Dilution risk is minimal as basic and diluted share counts are identical, implying no near-term equity issuance pressure.
- Data limitations prevent a comprehensive analysis of growth trends, segment performance, and geographic exposure.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,35 |
| Revenue | —no estimate | —no estimate | 9,5B CNY |
| Operating income | —no estimate | —no estimate | 551,3M CNY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Market Capmarket_price * shares_outstanding_diluted
- China Resources Medical Holdings Company Ltd Market data — financials · 2026-07-28
- reconciler_enqueue (reconciler) on 1515.HK · 2026-07-28
Ownership & reference
Leadership
- Chuang ZhangChief Executive Officer, Executive Director
- Qing SongExecutive Chairman of the Board
Insider activity
Short positioning
Geographic breakdown
Intel & risk
no material change vs prior analysis (walked 17 fields; 4 schema-expansion field(s) excluded)
- Narrative— → —medium
- Business summary— → —medium
- Conclusion— → —medium
- Key takeaways— → —medium